APA (7th ed.) Citation

Pi, J., He, X., Zhou, S., Liu, P., Yang, J., Wei, G., . . . Zhang, W. (2025). 1291eP Pola-R-CHP regimen as first-line treatment for newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) patients. Annals of Oncology, 36, S814. https://doi.org/10.1016/j.annonc.2025.08.1925

Chicago Style (17th ed.) Citation

Pi, J., et al. "1291eP Pola-R-CHP Regimen as First-line Treatment for Newly Diagnosed High-risk Diffuse Large B-cell Lymphoma (DLBCL) Patients." Annals of Oncology 36 (2025): S814. https://doi.org/10.1016/j.annonc.2025.08.1925.

MLA (9th ed.) Citation

Pi, J., et al. "1291eP Pola-R-CHP Regimen as First-line Treatment for Newly Diagnosed High-risk Diffuse Large B-cell Lymphoma (DLBCL) Patients." Annals of Oncology, vol. 36, 2025, p. S814, https://doi.org/10.1016/j.annonc.2025.08.1925.